Feb 26, 2026
Peter Busk
Cybersecurity in regulated industries
Introduction
A cyber attack on a pharmaceutical company is not just annoying downtime or data loss. It can mean:
Compromised patient data with GDPR fines in the millions
Sabotage of production processes with potential patient risk
Theft of intellectual property worth billions
Loss of compliance and production stops
At Hyperbolic, we work with cybersecurity both in the pharmaceutical industry and general software development. Regulated industries face unique challenges: Security must be balanced with compliance, legacy systems are often vulnerable, and the consequences of breaches are catastrophic.
The Regulatory Landscape
GxP and Cybersecurity: The FDA has made it clear that data integrity includes protection against cyber threats. EU GMP Annex 11 explicitly requires that computerized systems are protected against unauthorized access.
GDPR: The pharmaceutical industry handles enormous amounts of personal data from clinical trials and patient programs. GDPR fines can reach up to 4% of global revenue.
NIS2 Directive: The EU's Network and Information Security Directive 2 classifies the pharmaceutical industry as a "critical entity" with heightened cybersecurity requirements starting in 2024.
Unique Challenges in Regulated Industries
Challenge 1: Legacy Systems
Production lines in the pharmaceutical industry can operate for over 20 years. Equipment and software from the 1990s are not uncommon.
The Problem:
Windows XP or older operating systems without security updates
Embedded controllers with hardcoded passwords
Proprietary protocols without encryption
No network isolation
The Solution:
Network Segmentation: Isolate legacy systems on separate VLANs
Bastion Hosts: Restricted access through hardened intermediary systems
Application Whitelisting: Only allow approved applications to run
Compensating Controls: When direct update is not possible
At Hyperbolic, we implemented network segmentation for a manufacturing facility: Legacy SCADA systems isolated on air-gap networks, data transferred via a one-way diode to the corporate network for reporting.
Challenge 2: Validation vs. Updating
Traditional IT: "Update quickly, ask questions later." GxP IT: "Is this update validated?"
The Problem: Security updates can change system behavior. In GxP, it may require revalidation. But waiting to update increases security risks.
Best Practices:
Critical Updates (active exploitation):
Emergency change process
Risk assessment: Higher risk of NOT updating
Shortened testing focused on critical functions
Implementation within days
Important Updates:
Standard change process
Regression testing of GxP functionalities
Implementation within 30 days
Routine Updates:
Aggregate in scheduled maintenance windows
Full regression testing
Quarterly or semi-annual implementation
Challenge 3: Third-party Access
The pharmaceutical industry relies on vendors for equipment maintenance, often via remote access.
Risks:
Vendor security may be weak
Remote access can be abused
Lack of visibility into vendor activities
Solution - Vendor Access Management:
Just-in-time Access: Accounts activated only as needed
Privileged Access Management: All vendor sessions monitored and recorded
Network Isolation: Vendors can only access their own equipment
Two-factor Authentication: Required for all remote access
Session Recording: Video of all vendor activity for auditing
Practical Security Framework
Layer 1: Network Security
Segmentation: Divide networks into zones based on GxP impact and trust level:
Production Zone: GxP-critical systems, high isolation
Laboratory Zone: LIMS, analytical instruments
Corporate Zone: Email, file sharing, ERP
DMZ: Systems accessible from the Internet
Firewall Rules: Default deny, explicitly allow only necessary traffic between zones.
Implementation: During a facility migration, we implemented micro-segmentation with Palo Alto firewalls. Each production line on a separate VLAN. Lateral movement between lines not possible.
Layer 2: Identity and Access Management
The Principle of Least Privilege: Users are granted only the access they need for their jobs.
Role-Based Access Control:
Define roles based on job functions
Assign rights to roles, not individual users
Regular access reviews (minimum quarterly)
Two-Factor Authentication:
Required for all remote access
Required for privileged accounts
Implement for all users where possible
Password Policy:
Minimum 12 characters (14+ better)
Complexity requirements
90-day expiration for standard accounts, 60 days for privileged
No password reuse (last 12 passwords)
Account locking after 5 failed attempts
Layer 3: Endpoint Protection
Antimalware: Enterprise-class, centrally managed. But challenge in GxP: Cannot automatically update definitions without validation.
Solution:
Separate update plan for GxP vs non-GxP
Test updates in a validation environment first
Rapid implementation process for critical threats
Endpoint Detection and Response: Beyond traditional antivirus, this solution monitors behavior and can detect zero-day attacks.
Application Whitelisting: On critical systems, only allow approved applications. Blocks unknown malware by default.
Layer 4: Data Protection
Encryption:
At Rest: All databases and file systems containing sensitive data
In Transit: TLS 1.2+ for all network communication
Backups: Encrypted before external storage
Data Loss Prevention: Monitor and block attempts to remove sensitive data via email, USB, cloud storage.
Backup and Recovery:
The 3-2-1 Rule: 3 copies, 2 different media types, 1 offsite
Immutable Backups: Cannot be altered or deleted, protects against ransomware
Regular Testing: Quarterly recovery testing, annual disaster exercise
Layer 5: Monitoring and Incident Response
Security Information and Event Management: Centralized logging and correlation of events across all systems.
Key Use Cases:
Failed login attempts (potential brute force)
Privilege escalation
Access outside normal working hours to critical systems
Patterns of data exfiltration
Malware detections
Security Operations Center: For larger organizations, 24/7 monitoring.
Alternatives for Smaller Organizations:
Managed Security Service Provider: Outsourced Security Operations Center
Part-Time Monitoring: Daily review of alerts
Automated Alerts: Critical incidents trigger immediate response
Incident Response Plan:
Recognition: How are incidents identified?
Containment: Isolate affected systems
Eradication: Remove threat
Recovery: Restore systems
Lessons Learned: Post-incident review
GxP-Specific Additions:
Impact Analysis: Does the incident affect data integrity?
Regulatory Notification: When should the FDA/EMA be informed?
Deviation: Is the incident a GxP deviation?
Common Attack Vectors in the Pharmaceutical Industry
Phishing and Social Engineering
Tactics: Emails that appear legitimate from suppliers, colleagues, or supervisors.
Defense:
Security Awareness Training: Quarterly for all employees, phishing simulations
Email Filtering: Block known malicious senders, suspicious attachments
DMARC/SPF/DKIM: Email authentication to prevent spoofing
Reporting Mechanism: Easy way for users to report suspicious emails
Ransomware
Consequences: Encryption of critical data with ransom demands. Can halt production for days or weeks.
Defense:
Immutable Backups: Primary defense, can recover without paying
Network Segmentation: Limits spread
Application Whitelisting: Blocks unknown ransomware
User Education: Do not open suspicious attachments
Example: A customer was hit by ransomware. Thanks to daily immutable backups, they were operational again within 36 hours without paying. Estimated cost of paying the ransom plus downtime during recovery: 1.5 million kroner. Actual cost: 400,000 kroner (primarily IT overtime).
Supply Chain Attacks
Tactics: Compromise software from trusted suppliers.
Example: SolarWinds hack (2020) where hackers infiltrated software updates from a major vendor.
Defense:
Vendor Security Assessment: Due diligence before onboarding
Software Composition Analysis: Scan for known vulnerabilities in third-party components
Isolated Update Testing: Test updates in a sandbox environment before implementation
Internal Threats
Types:
Malicious: Disgruntled employee sabotages or steals data
Negligent: Careless actions create vulnerabilities
Defense:
Least Privilege: Limit the damage an insider can do
User Behavior Analysis: Log abnormal activity
Separation of Duties: No single person has full control
Offboarding Procedures: Immediate revocation of access upon termination
Compliance and Audits
What Inspectors Look For:
Policies and Procedures:
IT Security Policy
Access Control Procedures
Incident Response Plan
Business Continuity Plan
Backup and Recovery Procedures
Technical Controls:
Demonstrate access controls (show user provisioning)
Review of audit trails (who accessed what and when)
Update management process
Status of malware protection
Testing and Exercises:
Results of penetration tests
Vulnerability scans
Documentation of disaster drills
Incident response exercises
Training Records: All users trained in security awareness.
Preparedness:
Gap Assessments: Internal or external
Gap Analysis: Compare current state to regulatory requirements
Remediation Tracking: Documented action plans for gaps
Example: Comprehensive Security Modernization
Background: Mid-sized biotech company, rapid growth, security was ad-hoc. FDA pre-approval inspection impending.
Findings from Initial Assessment:
No network segmentation (flat network)
Weak password policy (no complexity requirements)
No two-factor authentication
Inconsistent updates
Limited logging
No incident response plan
18-Month Transformation:
Phase 1 (Months 1-6) - Foundation:
Implemented network segmentation
Rolled out enterprise antivirus and endpoint protection
Enforced strong password policy
Rolled out two-factor authentication for all remote access
Established security information management with basic applications
Phase 2 (Months 7-12) - Maturity:
Implemented privileged access management
Established formal update management process
Developed incident response plan
Conducted tabletop exercise
Expanded applications for security information management
Phase 3 (Months 13-18) - Optimization:
Third-party penetration test
Remediated findings
Disaster exercise
Security awareness training program
Completed policies and procedures
Outcome of FDA Inspection: Zero security-related findings. Inspector praised mature security posture.
Cost vs. Breach
Investment in Security: 3.5 million kroner over 18 months (tools, consulting, employee time).
Cost of Potential Breach:
Average data breach in the pharmaceutical industry: 35 million kroner (IBM Security report)
Potential GDPR fine: Up to 400 million kroner+ (4% of revenue)
Production downtime: 750,000 kroner+ per day
Reputational damage: Incalculable
Return: Even without a breach, improvements in uptime and efficiency often justify the investment.
New Threats
AI-Driven Attacks: Sophisticated phishing with AI-generated content, automated exploitation of vulnerabilities.
Defense: AI-driven defense, behavior-based detection.
IoT Vulnerabilities: Medical devices, sensors, connected equipment often have weak security.
Defense: Network isolation, regular firmware updates, vendor security requirements.
Cloud Misconfigurations: As the pharmaceutical industry moves to the cloud, misconfigurations create exposure.
Defense: Cloud security posture tools, infrastructure-as-code with built-in security.
Conclusion
Cybersecurity in regulated industries requires a balance between protection and operational efficiency, between rapid response and validated changes.
Key Principles:
Defense in Depth: Multiple layers of security
Risk-Based Approach: Focus resources where the risk is greatest
Compliance Integration: Security and GxP hand in hand
Continuous Improvement: Threats evolve, so must your defense
At Hyperbolic, we help companies build security programs that both protect and enable the business.
Contact us for a cybersecurity assessment.
By
Peter Busk
CEO & Partner
[ HyperAcademy ]
